Compare State Street SPDR S&P Biotech ETF (XBI) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Consumer Staples Select Sector SPDR Fund — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.85, while Consumer Staples Select Sector SPDR Fund trades at $83.38. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| XBI | XLP | |
|---|---|---|
Sector | Broad Market / Factor | — |
52-Week High | $169.55 | $90.00 |
52-Week Low | $93.43 | $75.61 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
XLP trades at $84.02, down 0.66% amid broader market volatility. The technical picture shows bearish momentum with key support at $83 and resistance at $85. Analyst sentiment remains strongly positive with 100% buy ratings, while recent news highlights XLP's defensive positioning during economic uncertainty as consumer spending shows signs of moderation.
XLP offers defensive exposure with strong institutional support, though technical weakness and economic headwinds create near-term pressure. The ETF's low expense ratio and dividend yield provide stability, but sector rotation risks and consumer spending trends warrant monitoring for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
